Revive Therapeutics (RVV) Ratios

132 Followers

Revive Therapeutics Ratios

TSE:RVV's free cash flow for Q4 2025 was C$0.00. For the 2025 fiscal year, TSE:RVV's free cash flow was decreased by C$ and operating cash flow was C$0.00. See a summary of the company’s cash flow.

Ratios	TTM	Sep 25	Sep 24	Sep 23	Sep 22
Liquidity Ratios
Current Ratio	―	0.02	0.34	0.68	1.00
Quick Ratio	―	0.02	0.34	0.68	1.00
Cash Ratio	―	<0.01	0.25	0.61	0.94
Solvency Ratio	―	-3.01	-1.65	-1.76	-4.00
Operating Cash Flow Ratio	―	-0.23	-0.99	-1.75	-3.13
Short-Term Operating Cash Flow Coverage	―	0.00	-130.51	-44.81	-120.88
Net Current Asset Value	C$ ―	C$ -3.59M	C$ -2.26M	C$ -1.25M	C$ -298.56K
Leverage Ratios
Debt-to-Assets Ratio	―	0.33	<0.01	0.02	0.02
Debt-to-Equity Ratio	―	-0.02	<0.01	0.02	0.03
Debt-to-Capital Ratio	―	-0.02	<0.01	0.02	0.03
Long-Term Debt-to-Capital Ratio	―	-0.02	0.00	<0.01	<0.01
Financial Leverage Ratio	―	-0.06	1.47	1.34	1.35
Debt Service Coverage Ratio	―	-2.95K	-115.35	-31.20	-103.59
Interest Coverage Ratio	―	-441.42	-141.10	-125.49	-281.18
Debt to Market Cap	―	<0.01	<0.01	0.01	<0.01
Interest Debt Per Share	―	<0.01	<0.01	<0.01	<0.01
Net Debt to EBITDA	―	>-0.01	0.14	0.34	0.20
Profitability Margins
Gross Profit Margin	―	0.00%	0.00%	0.00%	0.00%
EBIT Margin	―	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	―	0.00%	0.00%	0.00%	0.00%
Operating Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Pretax Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Net Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Continuous Operations Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Net Income Per EBT	―	100.00%	100.00%	100.00%	100.15%
EBT Per EBIT	―	667.87%	170.98%	114.49%	99.85%
Return on Assets (ROA)	―	-5370.77%	-52.83%	-44.35%	-104.50%
Return on Equity (ROE)	―	318.64%	-77.69%	-59.34%	-141.51%
Return on Capital Employed (ROCE)	―	49.82%	-44.94%	-51.04%	-138.25%
Return on Invested Capital (ROIC)	―	49.82%	-44.63%	-49.81%	-135.97%
Return on Tangible Assets	―	-5370.77%	-446.81%	-249.97%	-390.63%
Earnings Yield	―	-131.18%	-147.67%	-41.39%	-12.12%
Efficiency Ratios
Receivables Turnover	―	0.00	0.00	0.00	0.00
Payables Turnover	―	<0.01	<0.01	<0.01	<0.01
Inventory Turnover	―	0.00	0.00	0.00	0.00
Fixed Asset Turnover	―	0.00	0.00	0.00	0.00
Asset Turnover	―	0.00	0.00	0.00	0.00
Working Capital Turnover Ratio	―	0.00	0.00	0.00	0.00
Cash Conversion Cycle	―	-3.90M	-2.87M	-2.24M	-2.47M
Days of Sales Outstanding	―	0.00	0.00	0.00	0.00
Days of Inventory Outstanding	―	0.00	0.00	0.00	0.00
Days of Payables Outstanding	―	3.90M	2.87M	2.24M	2.47M
Operating Cycle	―	0.00	0.00	0.00	0.00
Cash Flow Ratios
Operating Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.04
Free Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.04
CapEx Per Share	―	0.00	0.00	0.00	0.00
Free Cash Flow to Operating Cash Flow	―	1.00	1.00	1.00	1.00
Dividend Paid and CapEx Coverage Ratio	―	0.00	0.00	0.00	0.00
Capital Expenditure Coverage Ratio	―	0.00	0.00	0.00	0.00
Operating Cash Flow Coverage Ratio	―	-12.08	-130.51	-27.43	-39.85
Operating Cash Flow to Sales Ratio	―	0.00	0.00	0.00	0.00
Free Cash Flow Yield	―	-9.62%	-86.49%	-39.46%	-8.88%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-0.76	-0.68	-2.42	-8.25
Price-to-Sales (P/S) Ratio	―	0.00	0.00	0.00	0.00
Price-to-Book (P/B) Ratio	―	-2.43	0.53	1.43	11.67
Price-to-Free Cash Flow (P/FCF) Ratio	―	-10.39	-1.16	-2.53	-11.26
Price-to-Operating Cash Flow Ratio	―	-10.39	-1.16	-2.53	-11.26
Price-to-Earnings Growth (PEG) Ratio	―	>-0.01	0.03	0.04	0.32
Price-to-Fair Value	―	-2.43	0.53	1.43	11.67
Enterprise Value Multiple	―	-0.77	-0.54	-2.43	-8.09
Enterprise Value	―	8.44M	3.01M	13.40M	143.50M
EV to EBITDA	―	-0.77	-0.54	-2.43	-8.09
EV to Sales	―	0.00	0.00	0.00	0.00
EV to Free Cash Flow	―	-10.45	-0.91	-2.22	-10.99
EV to Operating Cash Flow	―	-10.45	-0.91	-2.22	-10.99
Tangible Book Value Per Share	―	>-0.01	>-0.01	>-0.01	<0.01
Shareholders’ Equity Per Share	―	>-0.01	0.02	0.03	0.04
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	>-0.01	>-0.01
Revenue Per Share	―	0.00	0.00	0.00	0.00
Net Income Per Share	―	-0.03	-0.01	-0.02	-0.06
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.00	1.00	1.14	1.00
Research & Development to Revenue	―	0.00	0.00	0.00	0.00
SG&A to Revenue	―	0.00	0.00	0.00	0.00
Stock-Based Compensation to Revenue	―	0.00	0.00	0.00	0.00
Income Quality	―	0.07	0.59	0.95	0.73

Currency in CAD